Home | Journal for ImmunoTherapy of Cancer

Latest Articles

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using ⁹⁰Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models
Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al

Case report

Spontaneous tumor regression following COVID-19 vaccination(3 March, 2022)
Position article and guidelines

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy(29 February, 2024)
Immune cell therapies and immune cell engineering

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study(13 December, 2022)
Clinical/translational cancer immunotherapy

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial(12 February, 2024)
Commentary

CARs are sharpening their weapons(31 January, 2024)